| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
This compound functions as an antioxidant. It does not target a specific protein but exerts its effects by scavenging free radicals and chelating metal ions, thereby protecting cellular membranes from oxidative damage.
|
|---|---|
| ln Vitro |
The compound exhibits strong lipid peroxidation inhibitory activity. It serves as an antioxidant agent, and studies have shown it can effectively inhibit the oxidation of lipids in various in vitro assay systems, demonstrating concentration-dependent activity.
|
| ln Vivo |
Dedicated in vivo efficacy studies for this specific flavonoid glycoside are not extensively documented. As a natural antioxidant, it is expected to provide protection against oxidative stress in animal models, but detailed bioavailability and efficacy data require further investigation.
|
| Enzyme Assay |
The lipid peroxidation inhibitory activity is typically assessed using the thiobarbituric acid reactive substances (TBARS) assay. Liposomes or microsomes are incubated with an initiator (e.g., Fe2+/ascorbate) and varying concentrations of the test compound. Malondialdehyde (MDA) formation is measured.
|
| Cell Assay |
Antioxidant activity is measured using cell-based oxidative stress models. Cells are pre-treated with the compound, followed by exposure to an oxidant such as hydrogen peroxide (H2O2). Cell viability, ROS levels (measured by DCFH-DA probe), and lipid peroxidation (C11-BODIPY staining) are assessed.
|
| Animal Protocol |
Dedicated in vivo protocols for this compound are not well-documented. A standard protocol would involve oral administration to rodent models of oxidative stress (e.g., induced by carbon tetrachloride). Biomarkers of lipid peroxidation in serum and tissues would be measured.
|
| ADME/Pharmacokinetics |
PK properties for complex flavonoid glycosides like this are generally poor. The sugar moieties (rutinose and glucose) are typically deglycosylated in the gut before absorption. The aglycone quercetin is then metabolized. Oral bioavailability is likely very low.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for this specific natural compound is not available. As a component of edible plants, it is generally recognized as safe (GRAS). However, purified compound toxicity has not been formally evaluated in preclinical studies. Standard lab precautions apply.
|
| Additional Infomation |
According to reports, quercetin 3-rutin-7-glucoside is found in daylilies, datura, and other organisms with relevant data.
This compound is primarily used as an analytical reference standard for the quantification of flavonoids in plant extracts using HPLC. It is also a tool for studying the structure-activity relationships of complex flavonoid glycosides in antioxidant research. |
| Molecular Formula |
C33H40O21
|
|---|---|
| Molecular Weight |
772.658100000001
|
| Exact Mass |
772.206
|
| CAS # |
30311-61-6
|
| PubChem CID |
10190763
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-3.1
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
54
|
| Complexity |
1320
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
OC[C@H]1O[C@@H](OC2=CC(O)=C3C(C(=C(OC3=C2)C2C=CC(O)=C(O)C=2)O[C@@H]2O[C@H](CO[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)=O)[C@H](O)[C@@H](O)[C@@H]1O
|
| InChi Key |
SPUFXPFDJYNCFD-YQJBXTIASA-N
|
| InChi Code |
InChI=1S/C33H40O21/c1-9-19(38)23(42)26(45)31(49-9)48-8-17-21(40)25(44)28(47)33(53-17)54-30-22(41)18-14(37)5-11(50-32-27(46)24(43)20(39)16(7-34)52-32)6-15(18)51-29(30)10-2-3-12(35)13(36)4-10/h2-6,9,16-17,19-21,23-28,31-40,42-47H,7-8H2,1H3/t9-,16+,17+,19-,20+,21+,23+,24-,25-,26+,27+,28+,31+,32+,33-/m0/s1
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-5-hydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2942 mL | 6.4712 mL | 12.9423 mL | |
| 5 mM | 0.2588 mL | 1.2942 mL | 2.5885 mL | |
| 10 mM | 0.1294 mL | 0.6471 mL | 1.2942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
